Nirogacestat Hydrobromide
FDA-approved product (tablet, oral), marketed as Ogsiveo.
- Registered studies
- 1
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Gastrointestinal desmoid tumor
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other antineoplastic agents
- FDA pharmacologic class
- Gamma Secretase Inhibitor FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA64.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli47.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae33.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
1registered study names this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Nirogacestat Hydrobromide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Ergotamine TartrateExisting use: Headache, Migraine disorder59.6% AI-predicted activityagainst M. tuberculosis10 registered studies
- NitisinoneExisting use: Tyrosinemia59.6% AI-predicted activityagainst M. tuberculosis17 registered studies
- Tenapanor HydrochlorideExisting use: Constipation, Constipation disorder, Irritable bowel syndrome59.6% AI-predicted activityagainst M. tuberculosis2 registered studies
- Edoxaban TosylateExisting use: Atrial fibrillation, Deep vein thrombosis, Pulmonary embolism and 3 more59.5% AI-predicted activityagainst M. tuberculosis22 registered studies
- AprocitentanExisting use: Hypertension59.5% AI-predicted activityagainst M. tuberculosis14 registered studies
- PlecanatideExisting use: Constipation59.5% AI-predicted activityagainst M. tuberculosis15 registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more59.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- VemurafenibExisting use: Cancer, Cutaneous melanoma, Melanoma and 2 more59.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- IrbesartanExisting use: Cardiovascular disease, Chronic kidney disease, Chronic renal failure syndrome and 3 more59.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Dihydroergotamine MesylateExisting use: Migraine disorder59.4% AI-predicted activityagainst M. tuberculosis21 registered studies
- HalazepamExisting use: Anxiety59.4% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NisoldipineExisting use: Cardiovascular disease, Hypertension59.4% AI-predicted activityagainst M. tuberculosis6 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
NCT04195399 · start 2020-10-07
Registered record
- Registry ID
- NCT04195399
- Conditions
- Desmoid Fibromatosis; Recurrent Desmoid Fibromatosis; Unresectable Desmoid Fibromatosis
- Interventions
- Biospecimen Collection; Computed Tomography; Echocardiography Test; Magnetic Resonance Imaging; Nirogacestat Hydrobromide; Quality-of-Life Assessment; Questionnaire Administration; X-Ray Imaging
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Active not recruiting
- Start
- 2020-10-07
- Completion
- 2032-12-31
- Enrolment
- 31
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDesmoid Fibromatosis; Recurrent Desmoid Fibromatosis; Unresectable Desmoid FibromatosisInterventionBiospecimen Collection; Computed Tomography; Echocardiography Test; Magnetic Resonance Imaging +4 morePhasePhase 2Registry statusActive not recruiting